NAFLD is considered as the hepatic manifestation of the metabolic syndrome, which includes insulin resistance, obesity and hyperlipidemia. NASH is a progressive stage of NAFLD with severe hepatic steatosis, hepatocyte death, inflammation, and fibrosis. Currently, no pharmacological interventions specifically tailored for NASH are approved. Ovarian tumor domain, ubiquitin aldehyde binding 1 (OTUB1), the founding member of deubiquitinases, regulates many metabolism-associated signaling pathways. However, the role of OTUB1 in NASH is unclarified.

中文翻译：

---

OTUB1 通过抑制 TRAF6-ASK1 信号通路减轻 NASH

NAFLD被认为是代谢综合征的肝脏表现，包括胰岛素抵抗、肥胖和高脂血症。NASH 是 NAFLD 的进展阶段，伴有严重的肝脂肪变性、肝细胞死亡、炎症和纤维化。目前，没有批准专门针对 NASH 的药物干预措施。卵巢肿瘤结构域泛素醛结合 1 (OTUB1) 是去泛素化酶的创始成员，它调节许多代谢相关的信号通路。然而，OTUB1 在 NASH 中的作用尚不清楚。